Literature DB >> 34953959

This Month in JAAD Case Reports: March 2022. Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2.

Brett Sloan1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34953959      PMCID: PMC8695307          DOI: 10.1016/j.jaad.2021.12.031

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
A recent cross-sectional analysis of 666 patients with COVID-19 found that approximately 12% had changes to the oral mucosa. Transient anterior U-shaped lingual papillitis (11.5%), tongue swelling (6.6%), aphthous stomatitis (6.5%), burning sensation in the mouth (5.3%), and mucositis (3.9%) were the most common conditions described. Reactive infectious mucocutaneous eruption (RIME) is a term the Pediatric Dermatology Research Alliance proposed to include pathogens associated with post-infectious mucositis, in addition to Mycoplasma pneumonia. Although mycoplasma-induced rash and mucositis are specific to 1 cause, RIME encompasses cases attributed to rhinoviruses, enteroviruses, parainfluenzavirus 2, influenza B virus, and Chlamydia pneumonia, among others. In the December 2021 edition of Journal of the American Academy of Dermatology Case Reports, Ryder et al report a severe case of RIME in a 17-year-old male after developing COVID-19. He initially presented with cough, fever, and fatigue and tested positive for SARS-CoV-2. A week later, he presented to the emergency department with pharyngitis and mucosal sloughing of the lips, hard and soft palates, and tonsillar pillars. After an extensive infectious disease work up and ruling out multisystem inflammatory syndrome in children, he was admitted for 5 days and treated with systemic corticosteroids. Four days after discharge, he was readmitted with worsening oral and new peri-urethral mucositis despite intravenous methylprednisolone. He began to improve shortly after starting cyclosporine and was completely clear of mucosal lesions approximately a week after his second admission. In a recent series of pediatric patients, 42% admitted to the hospital and 60% admitted to the pediatric intensive care unit for COVID-19 had mucocutaneous findings. Although multisystem inflammatory syndrome in children and toxic epidermal necrolysis/Stevens-Johnson syndrome need to be ruled out promptly in these patients, RIME should be added to the differential diagnosis.

Conflicts of interest

None disclosed.
  4 in total

1.  Mucocutaneous Eruptions in Acutely Ill Pediatric Patients-Think of Mycoplasma pneumoniae (and Other Infections) First.

Authors:  Michele L Ramien; Anna L Bruckner
Journal:  JAMA Dermatol       Date:  2020-02-01       Impact factor: 10.282

2.  Are Oral Mucosal Changes a Sign of COVID-19? A Cross-Sectional Study at a Field Hospital.

Authors:  A Nuño González; K Magaletskyy; P Martín Carrillo; B Lozano Masdemont; A Mayor Ibarguren; M Feito Rodríguez; P Herranz Pinto
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2021-02-27

3.  Mucocutaneous manifestations in children hospitalized with COVID-19.

Authors:  David Andina-Martinez; Montserrat Nieto-Moro; Jose Antonio Alonso-Cadenas; Juan Añon-Hidalgo; Angela Hernandez-Martin; Esther Perez-Suarez; Isabel Colmenero-Blanco; Maria Isabel Iglesias-Bouza; Julia Cano-Fernandez; Ana Mateos-Mayo; Antonio Torrelo
Journal:  J Am Acad Dermatol       Date:  2021-04-02       Impact factor: 11.527

4.  Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2.

Authors:  C Yoonhee Ryder; Elisabeth A Pedersen; Jennifer B Mancuso
Journal:  JAAD Case Rep       Date:  2021-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.